# Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma

Source: https://onco.cc/trials/nct07548177/  
OnCo record `nct07548177` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Anlotinib in sarcomas, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.

## Summary

Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma is a phase 2 interventional study registered as NCT07548177 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 33 participants planned, started 2026-04-02 and due to reach its primary completion in 2027-11. Interventions recorded: Benmelstobart injection combined with Anlotinib hydrochloride capsule.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07548177
- Phase: 2
- Setting: To Evaluate the Single-arm, Multi-center Phase II Clinical Trial of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Enrolled: 33

## Sources

- ClinicalTrials.gov NCT07548177: https://clinicaltrials.gov/study/NCT07548177

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct07548177.json